reduce dose; not more than 8 mg daily in severe liver disease
no information available; manufacturer advises avoid unless potential benefit outweighs risk
manufacturer advises avoid—no information available
constipation; headache, sensation of warmth or flushing, hiccups; occasional alterations in liver enzymes; hypersensitivity reactions reported; occasional transient visual disturbances and dizziness following intravenous administration; involuntary movements, seizures, chest pain, arrhythmias, hypotension and bradycardia also reported; suppositories may cause rectal irritation
oral and parenteral preparations not licensed for use in children under 2 years; suppositories not licensed for use in children
By slow intravenous injection or by intravenous infusion
5 mg/m2 immediately before chemotherapy (max. single dose 8 mg), then either repeat every 8–12 hours during chemotherapy and for at least 24 hours afterwards or give by mouth
8 mg immediately before chemotherapy, then either repeated every 8–12 hours during chemotherapy and for at least 24 hours afterwards or give by mouth
By mouth following intravenous administration
4 mg every 8–12 hours for up to 5 days
8 mg every 8–12 hours for up to 5 days
By intramuscular injection or by slow intravenous injection
100 micrograms/kg (max. 4 mg), as a single dose before, during, or after induction of anaesthesia
4 mg, as a single dose at induction of anaesthesia
for slow intravenous injection, give over 2–5 minutes
For intravenous infusion, dilute to a concentration of 320–640 micrograms/mL with Glucose 5% or Sodium Chloride 0.9% or Ringer's Solution; give over at least 15 minutes
Sub-sections
